Topical Clindamycin for MRSA Skin Lesions
Topical clindamycin is NOT appropriate for treating MRSA skin lesions—it is FDA-approved only for acne vulgaris, not for bacterial skin infections. 1
Why Topical Clindamycin Should Not Be Used
The FDA labeling explicitly states that topical clindamycin formulations (solution, gel, lotion) are indicated solely for acne vulgaris treatment 1. There is no evidence base or regulatory approval for using topical clindamycin against MRSA skin and soft tissue infections.
Appropriate Treatment Approach for MRSA Skin Lesions
Primary Intervention: Incision and Drainage
- Incision and drainage is the primary treatment for cutaneous abscesses 2
- For simple abscesses or boils, incision and drainage alone is often adequate 2
- Patients who receive incision and drainage have significantly better outcomes (71% success) compared to those who do not (43% success) 3
When to Add Systemic Antibiotics
Antibiotic therapy is recommended when abscesses are associated with 2:
- Severe or extensive disease (multiple sites)
- Rapid progression with associated cellulitis
- Signs of systemic illness
- Comorbidities or immunosuppression
- Extremes of age
- Difficult-to-drain locations (face, hand, genitalia)
- Lack of response to incision and drainage alone
Recommended Systemic Antibiotics for Outpatient MRSA
For empirical CA-MRSA coverage in outpatients with skin and soft tissue infections, use ORAL (not topical) agents 2:
- Clindamycin 600 mg PO three times daily (A-I evidence) 2
- Trimethoprim-sulfamethoxazole (A-II evidence) 2
- Doxycycline or minocycline (A-II evidence) 2
- Linezolid 600 mg PO twice daily (A-II evidence) 2
Treatment duration: 5-10 days, individualized based on clinical response 2
Pediatric Considerations
- For minor skin infections (impetigo) and secondarily infected lesions in children, mupirocin 2% topical ointment can be used 2—note this is mupirocin, NOT clindamycin
- For more significant MRSA infections requiring systemic therapy, oral clindamycin 10-13 mg/kg/dose every 6-8 hours is appropriate if local clindamycin resistance is <10% 2
- Tetracyclines should not be used in children <8 years of age 2
Critical Pitfalls to Avoid
Clindamycin Resistance Issues
- Always verify local clindamycin resistance rates before prescribing 2
- Inducible clindamycin resistance occurs in 29-47% of MRSA isolates in some populations 4
- D-test should be performed to detect inducible resistance and prevent treatment failure 4
Route of Administration Matters
- The FDA-approved topical clindamycin formulations contain alcohol base that causes eye/mucous membrane irritation 1
- Topical formulations achieve inadequate tissue concentrations for treating bacterial skin infections
- Systemic (oral or IV) clindamycin is required for MRSA skin infections 2, 5, 6
Clinical Outcomes Data
- Studies comparing oral clindamycin to trimethoprim-sulfamethoxazole show equivalent failure rates (25-26%) when combined with incision and drainage 3
- IV clindamycin (600-900 mg every 8 hours) shows comparable outcomes to vancomycin for hospitalized patients with MRSA skin infections 5
- Antibiotics combined with incision and drainage reduce failure rates from 60% to 25% 3